You are here

SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

Last updated on December 5, 2018

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Cell Carcinoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- First-line treatment in patients with metastatic renal cell carcinoma

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any previous systemic therapy of renal cell carcinoma except for adjuvant treatment

NCT00460798
Pfizer
Completed
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Pancreatic Cancer, Non-Small Cell Lung Cancer, Cancer
NCT03637491
All Genders
18+
Years
Multiple Sites
Non-Small Cell Lung Cancer, Urothelial Cancer
NCT03472560
All Genders
18+
Years
Multiple Sites
Non-Small-Cell Lung Carcinoma
NCT01034748
Males
18+
Years
Tacoma, Washington
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
NCT02499120
All Genders
18+
Years
Multiple Sites
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Cancer

This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before. The aim of the trial is to increase knowledge about quality of life, safety, efficacy and tolerability under conditions of routine use of Sutent. The individual observation period of each patient will be

1 year.

The Statistical Analysis Plan provides detailed specification of the analysis
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients treated by office-based oncologists, office-based urologists specialized in oncology or hospital-based oncologist/urologists
Renal Cell Carcinoma
Other: Sutent: observational study
SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Other Name: sunitinib malate
Non-Interventional Study
Intervention: Other: Sutent: observational study
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
356
September 2009
September 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • First-line treatment in patients with metastatic renal cell carcinoma

Exclusion Criteria:

  • Any previous systemic therapy of renal cell carcinoma except for adjuvant treatment
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00460798
A6181115
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer Inc
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2010

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now